Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.68 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.68 |
| ▸ | TDP2 | O95551 | 19/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | CASP9 | P55211 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.58 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5782680 | 0.84 | GRIA1 (0.78) | GRIA1CACNG8TDP2CASP3CASP7 | |
| SCHEMBL22904161 | 0.82 | TDP2 (0.60) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL22904230 | 0.82 | TDP2 (0.62) | GRIA1CACNG8TDP2CASP3CASP7 | |
| SCHEMBL10714302 | 0.81 | GRIA1 (1.00) | GRIA1CACNG8TDP2 | |
| SCHEMBL4895870 | 0.79 | GRIA1 (0.53) | GRIA1CACNG8 | |
| SCHEMBL22904088 | 0.78 | GSK3B (0.54) | GRIA1CACNG8CASP3CASP7CASP6 | |
| SCHEMBL13177568 | 0.76 | TDP2 (0.64) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL18010794 | 0.75 | TDP2 (1.00) | TDP2 | |
| SCHEMBL18010839 | 0.75 | TDP2 (1.00) | TDP2 | |
| SCHEMBL422023 | 0.75 | TDP2 (1.00) | TDP2CASP3CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |